AGILENT TECHNOLOGIES, INC.
NYSE: A·Santa Clara, California·CIK 0001090872
- Price
- $172.92
- Base IV
- $59.67
Valuation snapshot
At $172.92, the price is above even our bull case of $86.24.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $59.67
- 35% of the price · range $31.65–$86.24
- Price vs base case
- 190% above
- $172.92 against $59.67
- Base case · our researched forecast, 2026-11-11See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $31.65 to bull $86.24. Values per share.
Price against each value
- Bear case
- $31.65
- Price 446% above
- No growth
- …
- —
- Base case
- $59.67
- Price 190% above
What does Agilent Technologies do?
Agilent Technologies provides laboratory instruments, software, and consumables to help researchers and pharmaceutical companies analyze, identify, and quantify biological and chemical substances.
It brought in $7.4B of sales in the 12 months to Jul 2026.
Led by Padraig McDonnell, President and Chief Executive Officer since 2024. Padraig McDonnell Assumes Agilent CEO Role
- Industry
- Semiconductors
- Based in
- Santa Clara, California
- Trades on
- NYSE as A
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Jul 2026, about 20¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 46¢ of every dollar.
- Making what it sells46¢
- Research and development7¢
- Sales, marketing and admin25¢
- Tax3¢
- Left as profit20¢
Who pays Agilent Technologies, and for what?
Agilent sells laboratory instruments, software, services and consumables used in life sciences, diagnostics and applied testing. It earns revenue from product sales and from services and supplies that support laboratory workflows.
Its customers include pharmaceutical and biotechnology companies, clinical and commercial laboratories, hospitals, universities, government agencies and businesses in food, environmental, chemical and advanced-materials markets.
Life Sciences and Diagnostics Markets
39%Instruments, reagents, software, consumables, diagnostic products and specialty manufacturing services for research, clinical testing and pharmaceutical customers.
Agilent CrossLab
42%Laboratory services, consumables, software and automation that support customers’ lab operations and workflows.
Applied Markets
19%Instruments and software for chemical, environmental, food, forensic and materials testing, including gas chromatography, spectroscopy and vacuum products.
Where its work physically happens, beyond headquarters:
- Frederick nucleic acid manufacturing facility — Frederick, United States. The facility manufactures therapeutic nucleic acid ingredients, and Agilent's $725 million expansion is intended to double its production capacity.
- Waldbronn manufacturing facility — Waldbronn, Germany. The facility manufactures liquid chromatography instruments, automated electrophoresis products and supplies for Agilent's laboratory customers.
- Shanghai manufacturing center — Shanghai, China. This strategic manufacturing hub produces customized gas chromatography instruments and integrates research, quality assurance and supply chain operations for Agilent's largest market outside the United States.
- Singapore instrument manufacturing facility — Singapore, Singapore. The facility manufactures scientific instruments and reported an 80% increase in output from its advanced manufacturing program.
- Penang manufacturing facility — Bayan Lepas, Malaysia. This strategic factory makes customized instrument components and houses a global instrument design center and biochemical reliability laboratory.
How is the business doing?
Sales grew from $5.3B in 2020 to $6.9B in 2025, about 5% a year.
Running the business leaves about 22¢ of each sales dollar as operating profit, up from 16¢ in 2020.
After paying for its upkeep and new investment, it had $1.3B of cash to spare in the 12 months to Jul 2026.
What does management say it's aiming for?
Agilent says it exists to advance quality of life by delivering trusted answers and insights.
“We deliver trusted answers and insights to advance the quality of life.”
Who is responsible for the plan?
- Padraig McDonnellPresident and Chief Executive Officer
Leads Agilent's overall strategy and operations as President and CEO. Agilent sells analytical and clinical laboratory instruments, software, services and consumables across its business groups, and all of them report up to the CEO.
- Angelica RiemannSenior Vice President, Agilent, and President, Agilent CrossLab Group
Leads the Agilent CrossLab Group, which covers services, software and informatics, automation and consumables. CrossLab brings in recurring revenue from lab services, consumables and software that support customers' installed instruments, and Agilent reported it as about 42% of company revenue at its 2024 reorganization.
- August SpechtSenior Vice President and Chief Technology Officer
Leads Agilent's company-wide technology strategy, development and innovation work. Technology development feeds the instruments, software and consumables that Agilent sells to life sciences, diagnostics and applied-markets labs.
Roles checked November 6, 2026.
What management says it is working on now:
Improve the customer experience
Management says its primary focus includes improving how customers experience Agilent’s products and services.
Agilent Technologies 2025 Form 10-KDifferentiate its offerings
Management says it is focused on delivering product solutions that stand out for customers and meet their needs.
Agilent Technologies 2025 Form 10-KImprove productivity and protect margins
Agilent is pursuing supply-chain improvements, targeted pricing and cost-efficiency measures to address inflation and tariffs while supporting growth.
Agilent Technologies 2025 Form 10-KInvest in strategic research and development
The company says it plans significant research and development spending, focused on strategic opportunities and products with growth potential.
Agilent Technologies 2025 Form 10-K
- FY2026 revenue, FY2026
- $7.50 billion to $7.55 billion; core growth of 5.8% to 6.0%
- Agilent Q3 2026 Earnings Call Transcript
- FY2026 non-GAAP EPS, FY2026
- $6.18 to $6.21, including the Q3 tariff refund benefit
- Agilent Q3 2026 Earnings Call Transcript
What's changing right now?
Growth is holding steady. In Q3 2026 it sold 8% more than a year earlier. The year before, quarters averaged 9%.
Its operating margin is wider than a year ago: 24¢ per sales dollar, against 21¢.
Since Oct 2026 the share price has fallen 5%, from $181.15 to $172.92.
Recently
August 26, 2026
Life Sciences and Diagnostics quarterly revenue changed to $746.0M
FY2026 Q3 results, segment tableAugust 26, 2026
CrossLab share of quarterly revenue changed to 41.9%
FY2026 Q3 results, segment tablesJuly 31, 2026
Fiscal Q3 life sciences and diagnostics revenue changed to $746.0M
Agilent Q3 FY2026 Form 10-Q
Coming up
Expected after the quarter ending Oct. 31, 2026
FY2026 fourth-quarter results
Agilent gave fourth-quarter revenue guidance of $1.98 billion to $2.00 billion and non-GAAP EPS guidance of $1.71 to $1.74.
Agilent Q3 2026 Earnings Call TranscriptRevenue expected to begin in 2027
Specialty CDMO capacity expansion
Management described new capacity supporting specialty CDMO growth, with revenue expected to begin coming in during 2027.
Agilent Technologies Earnings Call TranscriptsLaunched September 4, 2026
Digital pathology product launch
Agilent announced a U.S. launch of its S540MD Slide Scanner System, expanding its digital pathology offering.
Agilent News & Events
Our own estimate moved too: the base case went from $48.37 to $59.67 a share between our last two valuations. The biggest reason: Life Sciences and Diagnostics quarterly revenue moved from an unreported prior value to $746.0M, as reported in FY2026 Q3 results, segment table.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Customer spending may weaken
Demand depends partly on customer capital spending, research budgets and government funding. Delays or cuts can reduce orders and make quarterly results harder to predict.
From the company's own filingsWould hit how fast sales growAgilent Technologies 2025 Form 10-K
Intense competition and rapid technology change
If Agilent does not bring successful products and services to market in time, customer demand may shift to competitors or newer technologies, reducing revenue.
From the company's own filingsWould hit how fast sales growAgilent Technologies 2025 Form 10-K
Trade rules and tariffs could raise costs
Tariffs, export controls and changing trade relationships may increase costs, disrupt supply chains or limit Agilent’s ability to ship products. Management said tariff-related costs began affecting results in the second half of FY2025.
From the company's own filingsWould hit how much of each sale it keepsAgilent Technologies 2025 Form 10-K
Regulatory requirements may affect products and sales
Some products are subject to health and diagnostic regulations. Failure to comply, or stricter rules, could increase costs, delay sales, or lead to product recalls or limits on sales.
From the company's own filingsWould hit how much of each sale it keepsAgilent Technologies 2025 Form 10-K
Supply disruptions can hinder production
Some custom components have limited alternative suppliers. Shortages, longer lead times or unexpected demand changes could delay shipments or leave Agilent with excess inventory.
From the company's own filingsWould hit how fast sales growAgilent Technologies 2025 Form 10-K
Acquisitions may not deliver expected benefits
Integrating acquired companies can take time and cost more than expected. Agilent may not achieve the growth or other benefits it anticipated.
From the company's own filingsWould hit how much of each sale it keepsAgilent Technologies 2025 Form 10-K
Academic and government demand remained weak.
From our researchWould hit how fast sales growFY2026 Q2 prepared remarks
The latest profitability benefited from temporary tariff refunds.
From our researchWould hit how much of each sale it keepsFY2026 Q3 results
Is it a good business?
From 2016 to 2025 it earned between 13% and 20% on the capital invested in it, a median of 17%. Its cost of capital in the latest valuation is 9.4%; returns were above it in every one of the 9 years.
From 2016 to 2025 it earned between 11% and 24% on its shareholders' equity, a median of 21%.
Over 10 years its operating margin ranged from 15¢ to 24¢ per sales dollar, a median of 19¢. Gross margin ran from 51¢ to 55¢.
Cost of capital 9.4%
The number of shares has held roughly steady over the past year.
It owes $2.2B more than it holds in cash, about 1.3 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $172.92. Our put its value between $31.65 and $86.24, with $59.67 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $31.65
Agilent's recent recovery fades as laboratories delay purchases, leaving slower sales and less profit from each sale.
Base case, $59.67
Agilent's recent sales recovery continues at a steadier pace, while services and better efficiency gradually increase profit.
Bull case, $86.24
Agilent builds on its recent sales and profit gains as drugmakers invest more and laboratories keep buying its equipment, supplies and services.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 190%
For Agilent Technologies to be worth today's $172.92, sales would need to grow about 31.0% a year. We assume 5.5%. Over the last 5 years, sales grew 3.7% a year.
Or, if sales grow 5.5% as we assume, the price works with a profit margin of 67.0% (we assume 25.0%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 31.0% a year?
Try your own numbersWe're moderately sure of this range: it scores 61 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $59.67 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average5.5%
- Operating margin25.0%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$59.67 -65.5%


